- A 48-year-old man with chronic gout starts allopurinol. One month later he develops a diffuse painful maculopapular rash that becomes blistering with mucosal involvement; biopsy shows full-thickness epidermal necrosis. Laboratory studies reveal eosinophilia and elevated alanine transaminase. Which genetic factor most strongly predisposed this patient to the described adverse reaction?
Answer: Presence of the HLA-B*58:01 allele associated with severe cutaneous drug hypersensitivity
When you encounter severe cutaneous drug reactions with mucosal involvement and full-thickness epidermal necrosis, think Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN). These life-threatening hypersensitivity reactions have strong genetic predispositions that vary by drug and ethnicity.
This patient's presentation—diffuse maculopapular rash progressing to blistering with mucosal involvement, full-thickness epidermal necrosis, eosinophilia, and elevated liver enzymes—is classic for allopurinol-induced SJS/TEN. The HLA-B*58:01 allele creates a strong genetic predisposition to severe allopurinol hypersensitivity, particularly in Asian populations but also seen in other ethnicities. This HLA variant likely alters antigen presentation, triggering an exaggerated T-cell response to allopurinol or its metabolites.
Option B is incorrect because CYP2C9 variants don't significantly affect allopurinol metabolism—the drug is primarily metabolized by xanthine oxidase and aldehyde oxidase. Option C describes TPMT deficiency, which causes toxicity from thiopurine drugs (like azathioprine or 6-mercaptopurine), not allopurinol. These patients develop bone marrow suppression, not severe skin reactions. Option D's Factor V Leiden mutation causes venous thromboembolism risk but wouldn't produce the inflammatory hypersensitivity pattern described here.
For USMLE Step 1, memorize key HLA associations with drug hypersensitivity: HLA-B*58:01 with allopurinol, HLA-B*57:01 with abacavir, and HLA-B*15:02 with carbamazepine (especially in Han Chinese populations). These represent some of medicine's strongest pharmacogenetic associations and are high-yield testable material.
- A 25-year-old woman with a recurrent urinary tract infection is prescribed trimethoprim-sulfamethoxazole. Two weeks later she presents with bleeding gums and excessive bruising. Laboratory testing shows hemoglobin 9.2 g/dL, leukocyte count 2,200/µL, and platelet count 34,000/µL. Peripheral smear shows no schistocytes. Which mechanism best explains this patient's hematologic toxicity?
Answer: Immune-mediated destruction of hematopoietic precursors by drug-dependent antibodies
When you encounter drug-induced cytopenias on the USMLE, consider the mechanism of toxicity. Trimethoprim-sulfamethoxazole (TMP-SMX) is a classic cause of immune-mediated bone marrow suppression, particularly affecting all three cell lines (pancytopenia).
This patient's presentation - pancytopenia with bleeding gums and bruising developing weeks after starting TMP-SMX - is characteristic of drug-induced immune destruction. The sulfonamide component acts as a hapten, binding to hematopoietic precursor cells and triggering antibody formation. These drug-dependent antibodies then attack bone marrow precursors, causing suppression of red cell, white cell, and platelet production. The timing (2 weeks) allows for antibody development, and the absence of schistocytes rules out microangiopathic processes.
Choice B describes G6PD deficiency-related hemolysis, which would cause isolated anemia with Heinz bodies and hemolytic markers - not the pancytopenia seen here. Choice C incorrectly suggests physical marrow infiltration by drug metabolites, which doesn't occur with sulfonamides and would typically show a leukoerythroblastic picture on smear. Choice D misrepresents the pathophysiology - thrombopoietin suppression wouldn't cause pancytopenia, and this mechanism isn't associated with TMP-SMX toxicity.
Remember that TMP-SMX is a high-yield cause of drug-induced pancytopenia through immune mechanisms. Watch for the classic presentation: pancytopenia developing 1-3 weeks after starting the medication, without hemolytic markers or abnormal cell morphology suggesting other causes.
- A patient on digoxin develops toxicity after clarithromycin. Which mechanism best explains this?
Answer: P-glycoprotein inhibition
Clarithromycin blocks P-glycoprotein, the efflux transporter that limits digoxin absorption and drives its tubular secretion. With P-gp inhibited, digoxin levels rise and toxicity develops. The tempting distractor is hepatic CYP3A4 inhibition, but digoxin is not significantly metabolized by CYP3A4; its toxicity from clarithromycin is a transporter interaction, not a metabolic one.
- Which of the following medications is most likely responsible for this patient's symptom?
Answer: Lisinopril
The patient is experiencing a dry, persistent cough, a well-known predictable (Type A) adverse effect of ACE inhibitors, such as lisinopril. This cough is thought to be caused by the accumulation of bradykinin, which is normally degraded by angiotensin-converting enzyme. Losartan, an angiotensin II receptor blocker, does not affect bradykinin levels and is a common alternative. Hydrochlorothiazide and amlodipine are not typically associated with a chronic cough.
- The development of this condition is caused by antibodies directed against a complex of the anticoagulant and which of the following endogenous molecules?
Answer: Platelet factor 4
This patient has developed heparin-induced thrombocytopenia (HIT), an immune-mediated adverse drug reaction. HIT is caused by the formation of IgG antibodies against the heparin-platelet factor 4 (PF4) complex. The binding of these antibodies to platelets leads to their activation, aggregation, and clearance, causing thrombocytopenia. Paradoxically, this platelet activation also creates a prothrombotic state, leading to new or worsening thrombosis.
- Which of the following medications is most commonly implicated in this type of immune-mediated reaction?
Answer: Amoxicillin
Stevens-Johnson syndrome (SJS) is a severe, immune-mediated mucocutaneous reaction often triggered by medications. Penicillins (like amoxicillin) and sulfonamides are among the most common drug classes implicated in SJS. The reaction is a Type IV hypersensitivity reaction. While other antibiotics can cause SJS, penicillins are a classic cause. Doxycycline, metronidazole, and clindamycin are less frequently associated with SJS.
- A 55-year-old alcoholic man with cirrhosis is started on spironolactone and high-dose furosemide for ascites. One week later he develops gynecomastia and tender bilateral breast enlargement. Which property of spironolactone accounts for this adverse effect?
Answer: Androgen receptor antagonism leading to peripheral estrogen dominance
When you encounter adverse effects from medications, especially those involving hormonal changes like gynecomastia, think about the drug's mechanism and potential off-target effects on hormone receptors.
Spironolactone is a potassium-sparing diuretic that works by blocking aldosterone receptors in the distal nephron. However, due to structural similarities between steroid hormone receptors, spironolactone also has significant anti-androgenic activity. It blocks androgen receptors, preventing testosterone and other androgens from exerting their normal effects. This creates a relative estrogen dominance state, leading to feminizing effects like gynecomastia and breast tenderness. This adverse effect is dose-dependent and more common with higher doses, which explains why it appeared after starting treatment for ascites (which typically requires substantial doses).
Looking at the incorrect options: B) Spironolactone doesn't inhibit 11-β-hydroxylase - this enzyme is involved in cortisol synthesis and isn't affected by spironolactone. C) Carbonic anhydrase inhibition describes acetazolamide's mechanism, not spironolactone. D) Na⁺/K⁺/2Cl⁻ cotransport blockade describes loop diuretics like furosemide, which this patient is also receiving, but furosemide doesn't cause gynecomastia.
The correct answer is A - spironolactone's androgen receptor antagonism creates peripheral estrogen dominance.
Study tip: Remember that spironolactone has significant anti-androgenic effects beyond its diuretic action. This makes it useful for treating hirsutism and acne in women, but causes feminizing side effects in men, especially gynecomastia and decreased libido.
- The patient's cardiomyopathy is most likely a cumulative, dose-dependent toxicity of which of the following agents?
Answer: Doxorubicin
Doxorubicin, an anthracycline antibiotic used in chemotherapy, is well-known for causing a cumulative, dose-dependent cardiotoxicity. This predictable (Type A) adverse effect is mediated by the generation of free radicals, which damage cardiomyocytes and lead to dilated cardiomyopathy and heart failure. The risk increases significantly with higher cumulative doses. While trastuzumab can also cause cardiotoxicity (typically reversible), doxorubicin is the classic cause of this type of irreversible, dose-dependent cardiomyopathy.
- A patient on methotrexate develops pancytopenia after starting trimethoprim. Which mechanism explains this?
Answer: Additive DHFR inhibition
Methotrexate blocks dihydrofolate reductase (DHFR), and trimethoprim adds its own DHFR inhibition, so combined folate depletion impairs DNA synthesis in bone marrow and causes pancytopenia. The tempting wrong answer is reduced renal clearance, but that would mainly raise methotrexate levels and is not the primary additive mechanism producing marrow suppression.
- A 73-year-old man with atrial flutter is started on digoxin. One month later he complains of anorexia, nausea, and seeing yellow halos around lights. Serum creatinine is 2.1 mg/dL (baseline 1.0). His medication list includes lisinopril, furosemide, and amiodarone. Which concurrent therapy most likely precipitated his digoxin toxicity?
Answer: Long-term amiodarone that decreases digoxin clearance and displaces tissue binding
When you encounter digoxin toxicity questions, focus on the major factors that increase digoxin levels: decreased clearance, drug interactions, and renal impairment. This patient's classic symptoms (GI upset, visual changes) plus elevated creatinine suggest multiple contributing factors.
Amiodarone is a well-known culprit in digoxin toxicity through a dual mechanism. It inhibits P-glycoprotein pumps that normally clear digoxin from tissues, reducing renal and hepatic clearance by up to 50%. Additionally, amiodarone displaces digoxin from tissue binding sites, increasing free drug levels. This interaction typically manifests weeks after starting amiodarone, matching this timeline. Choice A correctly identifies this major drug interaction.
Choice B misunderstands diuretic effects - loop diuretics like furosemide actually cause hypokalemia (not metabolic alkalosis affecting protein binding), and low potassium increases digoxin toxicity through enhanced sodium-potassium pump inhibition, not protein binding changes.
Choice C incorrectly suggests ACE inhibitors potentiate vagal effects. While lisinopril can cause bradycardia, bradykinin accumulation doesn't directly increase digoxin levels or toxicity through vagotonia.
Choice D seems plausible since this patient has acute kidney injury, and reduced GFR does decrease digoxin clearance. However, the question asks which concurrent therapy "precipitated" the toxicity. The amiodarone-digoxin interaction is the primary pharmacological cause, while the renal impairment may be secondary or multifactorial.
Remember: Amiodarone interactions are high-yield for Step 1. It affects multiple drugs (digoxin, warfarin, statins) through P-glycoprotein and CYP enzyme inhibition. Always consider drug interactions when patients develop toxicity on stable doses.
- Which of his diabetes medications is the most likely cause of this presentation?
Answer: Metformin
The patient is presenting with high anion gap metabolic acidosis, specifically lactic acidosis. Metformin can cause lactic acidosis, a rare but serious predictable (Type A) adverse effect. The risk is significantly increased in patients with renal insufficiency, as metformin is cleared by the kidneys. Its accumulation inhibits hepatic gluconeogenesis from lactate, leading to elevated lactate levels. Glyburide causes hypoglycemia. Sitagliptin is generally well-tolerated. Empagliflozin can cause euglycemic diabetic ketoacidosis, not typically lactic acidosis.
- Which of the following antibiotics is the most likely cause of these findings?
Answer: Gentamicin
The patient has developed acute tubular necrosis (ATN), evidenced by the rising creatinine and muddy brown casts, along with ototoxicity (diminished hearing). These are classic, predictable (Type A) toxicities of aminoglycosides, such as gentamicin. These drugs accumulate in the renal proximal tubule cells and the endolymph of the inner ear, leading to nephrotoxicity and ototoxicity. The other listed antibiotics are not typically associated with this pattern of toxicity.
- A 65-year-old woman with type 2 diabetes and chronic kidney disease (estimated GFR 25 mL/min/1.73 m²) is maintained on metformin. She is admitted with septic shock requiring vasopressors. Twelve hours later, arterial blood gas shows pH 7.13, PaCO₂ 30 mm Hg, and HCO₃⁻ 10 mEq/L; serum lactate is 12 mmol/L. Which factor most directly contributed to this drug-induced metabolic derangement?
Answer: Accumulation of metformin due to impaired renal clearance causing mitochondrial inhibition
When you encounter a diabetic patient with severe metabolic acidosis and extremely high lactate levels, especially in the setting of kidney disease and metformin use, think metformin-associated lactic acidosis (MALA). This life-threatening condition occurs when metformin accumulates beyond therapeutic levels.
Metformin's primary mechanism involves inhibiting mitochondrial complex I in the electron transport chain, which normally produces minimal lactate at therapeutic doses. However, when metformin accumulates due to impaired renal clearance (as in this patient with GFR 25), the drug reaches toxic concentrations. This severe mitochondrial inhibition forces cells into anaerobic metabolism, massively increasing lactate production while decreasing lactate clearance. The septic shock further compounds this by creating tissue hypoxia and additional metabolic stress. Choice A correctly identifies this pathway.
Choice B incorrectly suggests respiratory acidosis, but the PaCO2 of 30 mm Hg shows respiratory compensation for metabolic acidosis. Choice C misrepresents the mechanism - metformin doesn't upregulate pyruvate dehydrogenase phosphatase; it directly inhibits mitochondrial respiration. Choice D is completely wrong as this scenario involves lactic acidosis, not ketoacidosis, and metformin doesn't inhibit lactate dehydrogenase.
Key takeaway: Always consider MALA in diabetic patients on metformin who develop severe lactic acidosis, especially with kidney disease, sepsis, or other conditions causing metformin accumulation. The combination of impaired clearance plus mitochondrial toxicity creates this dangerous metabolic crisis. - Disruption of which of the following fetal systems is the primary concern with her current class of medication?
Answer: Renal development and function
ACE inhibitors (e.g., lisinopril) and angiotensin II receptor blockers (e.g., losartan) are contraindicated in pregnancy, especially during the second and third trimesters. Their teratogenic effect is primarily due to disruption of the fetal renin-angiotensin system, which is crucial for fetal renal development and function. This can lead to fetal hypotension, anuria, and oligohydramnios, resulting in pulmonary hypoplasia and limb contractures (Potter sequence).
- Which of the following drugs is most likely responsible for these findings?
Answer: Clozapine
The patient has developed agranulocytosis, a severe form of neutropenia. This is a rare but life-threatening idiosyncratic adverse effect of clozapine. Due to this risk, patients on clozapine require regular monitoring of their white blood cell count. Other atypical antipsychotics like risperidone and olanzapine, and typical antipsychotics like haloperidol, have a much lower risk of causing agranulocytosis.
- During induction of general anesthesia, a 23-year-old man develops generalized muscle rigidity, hypercapnia, and a temperature of 40 °C minutes after administration of succinylcholine and sevoflurane. His father experienced a similar episode during surgery. Which drug should be administered immediately, and what is its mechanism of action?
Answer: Dantrolene—blocks ryanodine receptor–mediated calcium release from sarcoplasmic reticulum
When you encounter a patient developing muscle rigidity, hypercapnia, and hyperthermia during anesthesia with triggering agents like succinylcholine or volatile anesthetics, think malignant hyperthermia (MH). The family history strongly supports this autosomal dominant condition affecting calcium regulation in skeletal muscle.
Malignant hyperthermia occurs due to defective ryanodine receptors (RyR1) in the sarcoplasmic reticulum. When exposed to triggering agents, these abnormal receptors cause massive, uncontrolled calcium release into the muscle cytoplasm, leading to sustained muscle contraction, increased metabolism, heat production, and CO₂ generation. This creates the classic triad: rigidity, hypercapnia, and hyperthermia.
Option A is correct because dantrolene directly blocks the ryanodine receptors, preventing further calcium release from the sarcoplasmic reticulum and stopping the pathologic process at its source. It's the specific antidote for MH and must be given immediately.
Option B (bromocriptine) treats neuroleptic malignant syndrome, a different hyperthermic condition caused by dopamine blockade, not calcium dysregulation. Option C (flumazenil) reverses benzodiazepine effects but has no role in MH treatment. Option D (atropine) blocks muscarinic receptors and wouldn't address the fundamental calcium release problem causing MH.
Study tip: Remember the MH equation: triggering anesthetic + family history + triad (rigidity/hypercapnia/hyperthermia) = dantrolene immediately. Don't confuse this with neuroleptic malignant syndrome, which involves antipsychotics and requires different treatment.
- This patient's reaction is most likely due to the formation of toxic metabolites from which of the following drugs?
Answer: Isoniazid
Isoniazid (INH) is a cornerstone of tuberculosis treatment and prophylaxis and is well-known for causing idiosyncratic drug-induced liver injury. The hepatotoxicity is thought to be caused by toxic metabolites produced during its metabolism, which is influenced by N-acetyltransferase 2 (NAT2) acetylation status. Slow acetylators are at higher risk. While rifampin and pyrazinamide can also be hepatotoxic, INH is the classic cause of this type of delayed, idiosyncratic hepatitis. Ethambutol is associated with optic neuritis.
- Toxicity from which of the following medications best explains her presentation?
Answer: Lithium
The patient's neurologic symptoms (confusion, tremor, ataxia) are classic signs of lithium toxicity. Lithium is a narrow therapeutic index drug that is excreted by the kidneys. Its clearance can be significantly reduced by factors that decrease renal blood flow or increase sodium and water reabsorption, such as NSAID use, dehydration (from diarrhea), and thiazide diuretics. The recent addition of an NSAID likely decreased renal clearance of lithium, leading to toxic accumulation.
- A 63-year-old woman with metastatic breast cancer receives doxorubicin and cyclophosphamide. After 550 mg/m² cumulative doxorubicin dose, an echocardiogram shows an ejection fraction of 35% (baseline 60%). Which of the following agents could have reduced the risk of this complication if it had been co-administered from the first cycle?
Answer: Dexrazoxane, an iron-chelating cardioprotectant
When you encounter cardiotoxicity from chemotherapy, think about drug-specific protective agents and the mechanisms behind organ damage. Doxorubicin is an anthracycline antibiotic that causes dose-dependent cardiomyopathy through iron-catalyzed free radical formation, leading to irreversible myocardial damage.
Dexrazoxane (choice A) is the correct answer because it's an iron-chelating agent specifically designed to prevent anthracycline-induced cardiotoxicity. It works by binding iron ions, preventing the formation of iron-doxorubicin complexes that generate cardiotoxic free radicals. Studies show it significantly reduces the risk of cardiomyopathy when given with each doxorubicin cycle, especially important at cumulative doses above 300 mg/m².
Choice B (filgrastim) is incorrect because it's a G-CSF used to stimulate neutrophil production and prevent neutropenia—it has no cardioprotective properties. Choice C (mesna) protects against hemorrhagic cystitis from cyclophosphamide by neutralizing toxic metabolites in the bladder, but offers no cardiac protection against doxorubicin. Choice D (ondansetron) is an antiemetic that prevents chemotherapy-induced nausea and vomiting through 5-HT3 receptor antagonism—again, no cardiac benefit.
Remember that organ-specific toxicities from chemotherapy have corresponding protective agents: dexrazoxane for doxorubicin's cardiac toxicity, mesna for cyclophosphamide's bladder toxicity, and leucovorin for methotrexate's folate antagonism. Match the protective agent to the specific drug and organ system at risk.
- A patient on isoniazid has neuropathy, seizures, and sideroblastic anemia. Which mechanism explains all three?
Answer: Pyridoxine (B6) depletion
Isoniazid complexes pyridoxine and inhibits its activation, causing functional B6 deficiency. B6 is needed for heme synthesis and neurotransmitter production, so depletion produces sideroblastic anemia, neuropathy, and seizures. The tempting wrong answer is a CYP2E1-generated metabolite, which explains isoniazid hepatotoxicity, not these triad findings.
